Abstract
Neurotech Pharmaceuticals Inc is developing NT-501, an implantable polymeric device containing a genetically modified cell line that secretes ciliary neurotrophic factor, for the potential treatment of retinitis pigmentosa (RP) and age-related macular degeneration (AMD). Phase III clinical trials for RP and a phase II clinical trial for dry AMD are ongoing. A phase I clinical trial showed that NT-501 treatment was well tolerated with variable, but positive improvements in visual acuity.
MeSH terms
-
Cell Line / metabolism*
-
Cell Line / transplantation*
-
Cells, Immobilized / transplantation*
-
Ciliary Neurotrophic Factor / biosynthesis*
-
Ciliary Neurotrophic Factor / genetics
-
Clinical Trials as Topic
-
Humans
-
Macular Degeneration / genetics
-
Macular Degeneration / metabolism
-
Macular Degeneration / therapy*
-
Polymers*
-
Prostheses and Implants*
-
Retinitis Pigmentosa / genetics
-
Retinitis Pigmentosa / metabolism
-
Retinitis Pigmentosa / therapy*
Substances
-
Ciliary Neurotrophic Factor
-
Polymers